Redpoint Investment Management Pty Ltd boosted its position in shares of Zoetis Inc. (NYSE:ZTS – Get Rating) by 13.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,737 shares of the company’s stock after acquiring an additional 1,468 shares during the period. Redpoint Investment Management Pty Ltd’s holdings in Zoetis were worth $2,402,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of ZTS. New World Advisors LLC bought a new position in shares of Zoetis during the 3rd quarter worth about $341,000. Twinbeech Capital LP bought a new position in Zoetis during the third quarter worth about $402,000. Cetera Advisor Networks LLC boosted its holdings in Zoetis by 0.9% during the third quarter. Cetera Advisor Networks LLC now owns 7,635 shares of the company’s stock valued at $1,482,000 after purchasing an additional 68 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in shares of Zoetis in the 3rd quarter valued at approximately $2,361,000. Finally, Colony Group LLC raised its holdings in shares of Zoetis by 248.1% in the 3rd quarter. Colony Group LLC now owns 21,959 shares of the company’s stock worth $4,263,000 after buying an additional 15,651 shares in the last quarter. 90.73% of the stock is owned by hedge funds and other institutional investors.
In other Zoetis news, Director Willie M. Reed sold 1,855 shares of the company’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $162.31, for a total transaction of $301,085.05. Following the transaction, the director now directly owns 6,782 shares in the company, valued at approximately $1,100,786.42. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 2,167 shares of the firm’s stock in a transaction dated Tuesday, April 26th. The shares were sold at an average price of $178.96, for a total transaction of $387,806.32. Following the completion of the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at approximately $4,239,025.52. The disclosure for this sale can be found here. 0.12% of the stock is currently owned by company insiders.
Zoetis (NYSE:ZTS – Get Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.10. Zoetis had a net margin of 26.27% and a return on equity of 49.62%. The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $1.98 billion. During the same quarter last year, the company posted $1.26 EPS. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Zoetis Inc. will post 5.05 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Investors of record on Thursday, July 21st will be given a $0.325 dividend. This represents a $1.30 annualized dividend and a yield of 0.78%. The ex-dividend date of this dividend is Wednesday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 29.82%.
Several research firms have issued reports on ZTS. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 26th. Citigroup dropped their target price on shares of Zoetis from $232.00 to $208.00 and set a “neutral” rating for the company in a research report on Wednesday, March 9th. Finally, The Goldman Sachs Group cut their price target on shares of Zoetis from $237.00 to $208.00 and set a “buy” rating for the company in a report on Thursday, May 19th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $230.43.
Zoetis Profile (Get Rating)
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
- Get a free copy of the StockNews.com research report on Zoetis (ZTS)
- Worthington’s Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
- Here’s Why Boeing (NYSE: BA) Is Worth The Risk
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.